Thierry Chatellier
Saint-nazaire-en-royans, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 07, 2024
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: January 02, 2024
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
Journal: The lancet. Healthy longevity
Published: November 27, 2023
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.
Journal: Clinical lung cancer
Published: August 04, 2023
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Journal: Cancer immunology, immunotherapy : CII
Published: February 27, 2023
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Journal: Cancer immunology, immunotherapy : CII
Published: August 11, 2022
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.
Journal: Cancer medicine
Published: June 24, 2022
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.
Journal: Therapeutic advances in medical oncology
Published: June 17, 2022
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab.
Journal: Cancer immunology, immunotherapy : CII
Published: July 17, 2021
Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature.
Journal: Clinical case reports
Published: March 12, 2019
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Journal: International journal of cancer
Published: January 16, 2019
Last Updated: 09/26/2026